What's fueling the biotech engine?
- 1 October 2007
- journal article
- Published by Springer Nature in Nature Biotechnology
- Vol. 25 (10), 1097-1104
- https://doi.org/10.1038/nbt1007-1097
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Regulation of Follow-on BiologicsNew England Journal of Medicine, 2007
- Weighing the Hazards of Erythropoiesis Stimulation in Patients with CancerNew England Journal of Medicine, 2007
- Development trends for monoclonal antibody cancer therapeuticsNature Reviews Drug Discovery, 2007
- Correction of Anemia — Payoffs and ProblemsNew England Journal of Medicine, 2006
- The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular DegenerationNew England Journal of Medicine, 2006
- Biopharmaceutical benchmarks 2006Nature Biotechnology, 2006
- Uphill StruggleNature, 2006
- Off-label Reports of New Biologics: Exciting New Therapy or Dubious Research? Examples From Recombinant Activated Factor VIIJournal of Intensive Care Medicine, 2006
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- AdalimumabNature Reviews Drug Discovery, 2003